Stanford University is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Darrell Wilson, MD, the TrialNet team at Stanford University is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.   

The Hospital for Sick Children (SickKids) is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Diane Wherrett, MD, the TrialNet team at SickKids is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. 

TrialNet screening is unavailable to residents of the United Kingdom. Please contact trialnet-uk@bristol.ac.uk for more information.
The University of Bristol is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Yuk Fun-Liu, MD, the TrialNet team at University of Bristol is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. 

University of California, San Francisco (UCSF) is one of twenty-five Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Stephen Gitelman, MD, the TrialNet team at UCSF is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

The University of Chicago is one of twenty-five Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Principal Investigator, Lou Philipson, MD, the TrialNet team at the University of Chicago is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

The University of Florida (UF) is one of twenty-five Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Michael Haller, MD, the TrialNet team at UF is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Led by David Baidal, MD, the TrialNet team at University of Miami is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. 

Led by Inas Thomas, MD, the TrialNet team at University of Michigan is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

University of Minnesota is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Antoinette Moran, MD, the TrialNet team at University of Minnesota is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. 

University of Pittsburgh is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Ingrid Libman, MD, PhD, the TrialNet team at University of Pittsburgh is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. Our center is located at the Children's Hospital of Pittsburgh of UPMC.